Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
Alessandro Maglione, Marta Morra, Raffaella Meroni, Manuela Matta, Marinella Clerico, Simona Rolla
Topics & Concepts
MedicineOcrelizumabMultiple sclerosisBooster (rocketry)SeroconversionCladribineBooster doseVaccinationImmunologyAntibodyInternal medicineImmunizationRituximabPhysicsAstronomySARS-CoV-2 and COVID-19 ResearchPolyomavirus and related diseasesMultiple Sclerosis Research Studies